Selected "Top Doc 2012" by Northern Virginia Magazine: February 2012 Issue
Tue, 01/24/2012 - 12:54 — admin01/24/2012 - 17:52
Etc/GMT
Selected by peer and panel.
Selected "Top Doc 2011" by Northern Virginia Magazine: February Issue
Sun, 01/30/2011 - 18:50 — adminProstate Cancer Survival Improves With Radiotherapy And Androgen Deprivation Therapy
Sat, 11/05/2011 - 14:22 — adminAn article published Online First in The Lancet reveals that men with locally advanced prostate cancer, which has not spread, who receive radiotherapy (RT) in combination with their androgen deprivation therapy (ADT) are more likely to have a greater overall chance of survival compared with those on ADT alone.
FDA Grants Fast Track Designation For Alpharadin For Castration Resistant Prostate Cancer In Patients With Bone Metastases
Sun, 09/04/2011 - 12:24 — adminInvestigational drug Alpharadin (radium-223 chloride) for the treatment of castration-resistant prostate cancer in patients whose cancer has spread to the bone (bone metastasis) has been granted Fast Track designation by the FDA (Food and Drug Administration), Bayer Health Care announced today. Alpharadin is exclusively licenced to Bayer from Algeta ASA.
